Business & Finance

Repligen reports second quarter fiscal year 2007 financial results

Published in Drug Law Weekly, November 28th, 2006

Repligen Corporation (RGEN) reported results for the second quarter of fiscal year 2007, ended September 30, 2006 with total revenue for the second quarter, consisting primarily of Protein A and SecreFlo sales, of $2,865,000 compared to total revenue of $2,800,000 for the second quarter of fiscal year 2006.

Gross profit on product revenue for the second quarter of fiscal year 2007 was $1,765,000 (66%) compared to $1,844,000 (68%) for the second quarter of fiscal year 2006.

Operating expenses for the second quarter of fiscal year 2007 were $3,961,000 compared to $3,480,000 for the same period in fiscal year 2006. This increase in operating expenses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2006-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry